世界の内分泌検査市場2021年-2026年

Mordor Intelligenceが発行した調査報告書(MOR21JU431)
◆英語タイトル:Endocrine Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
◆商品コード:MOR21JU431
◆発行会社(リサーチ会社):Mordor Intelligence
◆発行日:2021年5月
◆ページ数:132
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2-3営業日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD4,250 ⇒換算¥467,500見積依頼/購入/質問フォーム
Team User(5名利用)USD4,750 ⇒換算¥522,500見積依頼/購入/質問フォーム
Corporate License(法人利用)USD7,500 ⇒換算¥825,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMordor Intelligence社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Mordor Intelligence社の概要及び新刊レポートはこちらでご確認いただけます。

本調査資料は、世界の内分泌検査市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、検査別(甲状腺検査、インスリン検査、ヒト絨毛性ゴナドトロピン検査、プロラクチン検査、黄体形成ホルモン検査、その他)分析、技術別(イムノアッセイ、タンデム質量分析、センサー技術、その他)分析、エンドユーザー別(病院、臨床研究所、その他)分析、地域別分析、競争状況、市場機会/将来の見通しなどを掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界の内分泌検査市場規模:検査別(甲状腺検査、インスリン検査、ヒト絨毛性ゴナドトロピン検査、プロラクチン検査、黄体形成ホルモン検査、その他)
・世界の内分泌検査市場規模:技術別(イムノアッセイ、タンデム質量分析、センサー技術、その他)
・世界の内分泌検査市場規模:エンドユーザー別(病院、臨床研究所、その他)
・世界の内分泌検査市場規模:地域別
・競争状況
・市場機会/将来の見通し
【レポートの概要】

The endocrine testing market was valued at USD 9,170.62 million in 2020 and is expected to reach USD 13,119.51 million by 2026, registering a CAGR of 6.15% during the forecast period.

During the Pandemic, many research studies have been demonstrated that people with thyroid disorders are more prone to the COVID 19 infection, thus creating a significant demand for various endocrine tests globally in order to check and manage the thyroid hormone levels. As per the January 2021 research study titled “Thyroid Function Analysis in 50 Patients with COVID-19: A Retrospective Study” , the results of the study demonstrated that the more severe the COVID-19, the lower the TSH and TT3 levels were, with statistical significance. The degree of the decreases in TSH and TT3 levels was positively correlated with the severity of the disease. Hence, the changes in serum TSH and TT3 levels are the important manifestations of the courses of COVID-19.

The growing prevalence of endocrine disorders and advancements in diagnostic technologies are primarily driving the market growth. Furthermore, the growing older population coupled with rising awareness about early diagnosis and treatment around the world is anticipated to boost the market growth. Endocrine testing refers to the measuring of levels of hormones secreted by the endocrine glands and diagnosis of various disorders such as obesity, diabetes, thyroid disease, and others. According to the International Federation in 2019, Diabetes approximately 463 million adults were living with diabetes and by 2045 it will rise to 700 million.

According to the World Health Organization, the prevalence of obesity had tripled in 2016, compared to the levels in 1975. About 1.9 billion adults, aged 18 years or above, were overweight. Of these, about 650 million were obese. These numbers roughly translate to 39% and 13% of the adults as overweight and obese, respectively. About 38 million children under the age of five were overweight or obese in 2019. In addition, alcohol consumption is one of the largest risk factors for various endocrine diseases and disabilities. Globally, high-income countries of the developed region have the highest alcohol consumption. This high consumption of alcohol is also serving as one of the major factors for the burden of the disease. Owing to the large demand for endocrine testing tools the market players are also focusing on product development and novel launches. For instance. in October 2018, DRG Diagnostics launched Free T4 ELISA test kits, The Free T4 ELISA Assay Kit is intended for the direct quantitative determination of free thyroxine in human serum.

The growing prevalence of diabetes, thyroid disorders in many of the countries around the globe is anticipated to further fuel the market growth. However, the high cost for the development of testing technologies is expected to impede market growth over the forecast period.

Key Market Trends
Thyroid Stimulating Hormone Testing (TSH) Anticipated to have Lucrative Growth
Thyroid-stimulating hormone (TSH) is produced by the pituitary gland and stimulates the thyroid gland to produce thyroxine and triiodothyronine which helps in metabolism. TSH testing used to measure thyroid level. The burden of thyroid disorders is increasing across the globe. For instance, as per the American Thyroid Association (ATA), an estimated 20 million Americans have some form of thyroid disease in 2019. It was estimated that more than 12 % of the U.S. population is anticipated to develop a thyroid condition during their lifetime. The major risk factors for thyroid-associated disorders are smoking, alcohol, and tobacco consumption. As per November 2019 study conducted by researchers from the Department of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, the results of the study demonstrated that Cigarette smoking is associated with a moderately higher level of FT4 and FT3, and lower TSH levels, which suggest partly opposing effects of alcohol consumption.

TSH measurement has recently gained a lot of importance in thyroid function testing mainly due to the technological developments in these tests facilitating cost-effective disease screening. TSH has also introduced new definitions of subclinical hypothyroidism or hyperthyroidism, along with delivering biochemical treatment targets. Furthermore, advancements in product technologies coupled with the growing affordability for healthcare is fueling the market growth. Mass spectroscopy is now used along with liquid chromatography for accurate results. This is believed to fuel market growth over the forecast period.

North America is Anticipated to Have Significant Share
North America is anticipated to have a significant share owing to the factors such as well-established healthcare infrastructure, high prevalence of obesity, advancements in diagnostic technologies, and new product launches. The less physical activity and growing prevalence of thyroid disorders are anticipated to fuel the market growth.

According to Health and Human Services (HHS), only less than 5% of adults participate in the 30 minutes of physical activity each day in the United States. More than 80% of adults do not meet the required guidelines for muscle strengthening and aerobic activities. This is leading to the consequences such as an imbalance of hormones due to obesity and diseases or conditions associated with the thyroid which is augmenting the demand for thyroid testing services. According to the American Cancer Society, it was estimated that about 44,280 new cases of thyroid cancer (12,150 in men and 32,130 in women) and about 2,200 deaths from thyroid cancer (1,050 men and 1,150 women) will be reported in the United States in 2021.

North America is likely to witness major growth in the coming years, owing to several initiatives, such as compulsory screening of newborns for congenital hypothyroidism, revolutionary research work on thyroid hormone function, cost-effective methods to detect thyroid cancer, promising research on Graves’ disease, which is likely to further lead to improved prognosis, and new preventive treatments of thyroid diseases.

In mexico the growth is attributed to the rising prevalence of the disorders coupled with innovative product launches. For instance, in 2018, MedTech pioneer Proteomics International Laboratories Ltd launched of its world leading predictive diagnostic test for diabetic kidney disease, “PromarkerD“ in Mexican Market. Hence, owing to the above-mentioned factors, the market studied is believed to grow over the forecast period in this region.

Competitive Landscape
Global endocrine testing market is moderately competitive and there are several local as well as international companies in this market. Market players are focusing on new product launches, product innovations and geographical expansion. The key market players operating in the market include Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., bioMérieux SA, F. Hoffmann-La Roche Ltd and Siemens AG among others.

Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

【レポートの目次】

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Endocrine Disorders and Increasing Geriatric Population
4.2.2 Advancements in Product Technologies
4.3 Market Restraints
4.3.1 High Cost of Advanced Endocrine Testing Devices
4.3.2 Lack of Awareness in Underdeveloped and Developing Countries
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Test
5.1.1 Thyroid Test
5.1.2 Insulin Test
5.1.3 Human Chorionic Gonadotropin Test
5.1.4 Prolactin Test
5.1.5 Luteinizing Hormone Test
5.1.6 Progesterone Test
5.1.7 Others
5.2 By Technology
5.2.1 Immunoassay
5.2.2 Tandem Mass Spectroscopy
5.2.3 Sensor Technology
5.2.4 Others
5.3 By End-User
5.3.1 Hospitals
5.3.2 Clincal Laboratories
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AB Sciex
6.1.2 Abbott Laboratories
6.1.3 Agilent Technologies, Inc.
6.1.4 Biomedical Technologies
6.1.5 bioMerieux SA
6.1.6 Bio-Rad Laboratories, Inc.
6.1.7 Danaher Corporation
6.1.8 DiaSorin S.p.A.
6.1.9 F. Hoffmann-La Roche Ltd
6.1.10 Hologic Inc.
6.1.11 Ortho Clinical Diagnostics
6.1.12 Qiagen N.V.
6.1.13 Quest Diagnostics
6.1.14 Siemens Healthineers AG
6.1.15 Thermo Fisher Scientific

7 MARKET OPPORTUNITIES AND FUTURE TRENDS



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の内分泌検査市場2021年-2026年(Endocrine Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026))]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆